Patients impacted by phishing email scheme

Baylor Regional Medical Center has notified 1,981 patients that their information was compromised when some of the medical center's affiliated physicians responded to phishing emails.

The Plano, Texas-based organization learned on Feb. 24 that phishing emails were sent to a small group of affiliated physicians who responded to the emails thinking that they were legitimate internal requests on or after Jan. 23, according to a notice. By responding to the email, the affiliated physicians may have inadvertently created an opportunity for unauthorized access to their email accounts.  

"When we learned of this, we immediately secured the affected email accounts and began an investigation, including hiring an outside forensics expert firm," according to Baylor's notification. "We undertook a comprehensive review of the affected affiliated physicians’ email accounts and confirmed that some of their emails contained patient information and may have included patient demographic information (for example, name, address, date of birth, or telephone number) and limited clinical information (for example, treating physician and/or department, diagnosis, treatment received, medical record number, medications, medical service code or health insurance information), and in a small number of instances, Social Security numbers."    

Baylor has no evidence that the information in the emails has been used in any way, but began notifying patients on April 25 as a precaution. They also established a dedicated call center to assist patients with any questions.

The organization said it has re-enforced education with staff regarding phishing emails and is reviewing enhancements to the technical safeguards currently in place to further protect employee email accounts from unauthorized access.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.